Table 1B.
Selected new mirBridge miRNA function predictions (see Table S1 for details). Same format as Table 1A
| miRNA | Function | q value | High-quality putative targets |
|---|---|---|---|
| 33 | statin pathway | 0.00155 | ABCA1, HMGCR |
| 203 | G alpha i pathway | 0.00532 | MAPK1, JUN, PCLD, SRC, MYEF2, F2RL2, PLD2, EPHB2 |
| 23 | apoptosis | 0.00801 | CHUK, APAF1, CASP7, CASP3, BCL2, BIRC4, IRF1, BNIP3L, LMNB1 |
| 205 | tight junction | 0.01195 | PRKCE, CLDN11, EPB41, CNKSR3, INADL, YES1, VAPA, MAGI2, PARD6G, CLDN8, PTEN, PRKCH, MLLT4, ACTB, PRKCA, PARD6B |
| 187 | antigen processing and presentation | 0.02192 | KIR2DL2, KIR2DL1, KIR2DS2, KIR2DS4, KIR2DS5, KIR2DL4, KIR2DL3, IFNA2, KIR2DL5A |
| 219 | nuclear receptors | 0.02806 | THRB, NR2C2, NR1I2, NR5A2, NR3C1, NR2C2, ESR1 |
| 17-5p/20/93.mr/106/519.d | JNK MAPK pathway | 0.0377 | MAP3K2, MAP3K5, MAP3K9, GAB1, MAP3K12, NR2C2, ZAK, DUSP8, MAPK9, DUSP10, MAP3K3, MAP3K11 |
| 124.2/506 | axon guidance | 0.04983 | CHP, ROCK1, NFATC1, SEMA6D, ITGB1, GNAI1, NRAS, GNAI3, SEMA6A, NRP1, NFAT5, EPHB4, PLXNA3, EPHA3, EPHA2, SEMA5A, ROCK2, SRGAP3, EFNB3, EFNB1, NCK2, GNAI2, SEMA6C, EFNB2 |
| 34a/449 | glycosphingolipid biosynthesis | 0.05144 | FUT1, FUT5, FUT9, GCNT2, B4GALT2 |
| 128 | GnRH signaling | 0.05144 | PRKY, PRKX, MAPK14, MAP2K7, PLCB1, MAP2K4, ADCY8, ADCY2, GRB2, HBEGF, EGFR, CDC42, ADCY6 |
| 24 | cytokine-cytokine receptor interaction | 0.05203 | IFNG, EDA2R, TNFRSF19, CCR4, FASLG, IL10RB, IL1A, CCR1, PDGFRA, PDGFRB, EDA, PDGFC, TNFSF9, IL2RA, IL21R, CX3CR1, IL8RB, EDAR, CCL18, TNFRSF1A, IL1R1, IL8RA, IL29, IL2RB, ACVR1B, FLT1, IL22RA2, IL19, TNF, CSF1R, CNTFR, CLCF1, |
| 33 | PGC-1α pathway | 0.0541 | YWHAH, CAMK4, PPARA, MEF2C, CAMK2G, PPP3CB, CAMK2G, PPARGC1A |
| 375 | purine metabolism | 0.0544 | PDE4A, PDE8A, PDE5A, PDE7B, ADCY9, PDE4D, PDE10A, POLR3G, PDE4D, POLR2, AADCY6, PDE11A |
| 141/200a | EGF/PDGF pathway | 0.0637 | GRB2, MAP2K4, STAT5A, EGFR, PRKCB1, CSNK2A1, JUN, TAL1 |
| 142-5p | ubiquitin mediated proteolysis | 0.07389 | VHL, UBE2D1, SMURF1, CUL2, UBE2A, WWP1, CUL3, UBE2B, CDC23, UBE2E3 |
| 101 | ubiquitin mediated proteolysis | 0.07681 | UBE2D1, UBE2D2, UBE2A, VHL, UBE2D3, UBE2G1, FBXW11, FBXW7, CUL3 |
| 142-3p | regulation of actin cytoskeleton | 0.07816 | ITGAV, APC, MYLK, RAC1, WASL, MYH10, ROCK2, ITGB8, CRK, CFL2, FGF23, MYH9 |
| 19 | Ca signaling | 0.07827 | EDNRB, ADRB1, GRM1, CALM1, CACNA1C, GRIN2A, CHP, SLC25A6, SLC8A1, ADCY7, ITPR1, PDE1C, ADCY1, ATP2B4, ADCY9, PRKACB, PLCB1, SPHK2, ERBB4, ITPKB, PTK2B |
| 24 | apoptosis | 0.1148 | BNIP3L, BCL2L11, BIRC4, FASLG, NFKBIE, HELLS, RIPK1, TRAF1, CASP10, TNFRSF1A, TNF, IRF1, IRF5 |
| 135 | integrin pathway | 0.122 | ROCK2, ITGA1, ITGA2, ARHGEF7, PTK2, ARHGEF6, ROCK1, AKT3, PLCG1, PAK7, ANGPTL2, RHO |
| 93.HD/291-3P/294/295/302/372/373/520 | nuclear receptors | 0.1342 | VDR, NR2C2, PPARA, ESR1, NR4A2, NR2E1, NPM1, NR2F2 |
| 27 | statin pathway | 0.1396 | ABCA1, LDLR, LPL, HMGCR |
| 33 | cell cycle | 0.1555 | CDK6, CCND2, CDC25A, RB1 |
| 383 | O-glycan biosynthesis | 0.1658 | GALNT13, GALNT11, GCNT4, GALNT1, GALNT7 |
| 148/152 | inositol phosphate metabolism | 0.1677 | SYNJ1, PTEN, PI4KA, PIK3CA, ITPKB, PLCB1, ITPK1 |
| 25/32/92/363/367 | phosphatidylinositol signaling | 0.1916 | SYNJ1, PTEN, ITPR1, BMPR2, PIP5K3, PIP5K1C, PIK3R1, PIK3R3, RPS6KA4, PRKAR2B, PCTK1, PRKCE, PIP4K2C, RPS6KB1, CALM3 |
| 30-3p | ubiquitin mediated proteolysis | 0.1928 | UBE2J1, UBE2K, UBE2G1, UBE2D1, UBE2D3 |
| 153 | insulin receptor signaling | 0.1934 | GRB2, PIK3R1, RPS6KA3, RPS6KB1, SORBS1, CAP1, IRS2, FOXO1, AKT3 |